ASCO 2025 Session Focuses on Expanding Access and Innovation in Lung Cancer Screening
CheckMate 816 Shows OS Benefit in Resectable NSCLC With 5-Year Follow-Up
Research Shows Palliative Care Disparities Among Hispanic Patients With Lung Cancer
ASCO 2025: REZILIENT1 Insights From Dr. Helena Yu
A Seat at the Table: Drs. Olazagasti, Velez Reflect on Research, Mentorship, and Collaboration at ASCO 2025
Phase 3 DeLLphi-304 Trial Shows Taralatamab Significantly Improves OS, PFS in Previously Treated SCLC